Financings in Brief: Spectral Diagnostics
This article was originally published in The Gray Sheet
Spectral Diagnostics: Announces that its North and South American marketing partner Dade International will exercise warrants to buy for $2 mil. 123,839 shares of common stock in Spectral. The warrants are related to an investment made in 1993 by Baxter, which has since sold its diagnostic manufacturing businesses (now operating under the name Dade) to Bain Capital. Spectral says that the purchase of the additional shares is "a result of the successful U.S. product introduction" of its Status CK-MB/Myoglobin panel test...
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.